In our research, we aimed to investigate the additional value of the BCT score in a cohort of early stage, ER+HER2- breast cancer patients who were undergoing adjuvant treatments guided by a 21-gene expression assay. The gene discussed is ERBB2; the disease is breast carcinoma.